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Abstract
Objectives: To estimate annual direct costs of early RA by resource component in an inception cohort, with reference to
four distinct treatment strategies: no disease modifying antirheumatic drugs (DMARDs), synthetic DMARDs only, biologic
DMARDs in the first year (‘first-year biologic’, FYB), and biologic DMARDs from the second year after inclusion (‘later-year
biologic’, LYB); to determine predictors of total and non-DMARD related costs.
Methods: The ESPOIR cohort is a French multicentric, prospective study of 813 patients with early arthritis. Data assessing
RA-related resource utilisation and disease characteristics were collected at baseline, biannually during the first two years
and annually thereafter. Costs predictors were determined by generalised linear mixed analyses.
Results: Over the 4-year follow-up, mean annual direct total costs per treatment strategy group were J3,612 for all patients
and J998, J1,922, J14,791, J8,477 respectively for no DMARDs, synthetic DMARDs only, FYB and LYB users. The main
predictors of higher costs were biologic use and higher Health Assessment Questionnaire (HAQ) scores at baseline. Being a
biologic user led to a higher total cost (FYB Rate Ratio (RR) 7.22, [95% CI 5.59–9.31]; LYB RR 4.39, [95% CI 3.58–5.39])
compared to non-biologic users. Only LYB increased non-DMARD related costs compared to all other patients by 60%.
Conclusions: FYB users incurred the highest levels of total costs, while their non-DMARD related costs remained similar to
non-biologic users, possibly reflecting better RA control.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease causing
chronic inflammation of the joints, often resulting in severe
functional disability. The prevalence of RA in most world regions
is under 1% of the population, [1] with an incidence of 0.2% to
0.5% [2].
In France, the mean annual direct cost of RA was estimated
(costs are expressed in J2007 by applying the evolution of the
consumption of care and medical goods price index in France. [3])
at J4,437 per patient in 2000 [4] and J9,345 in 2005. [5] Direct
costs increased following the introduction of highly effective
biologic disease modifying anti-rheumatic drugs (DMARDs),
available since 2000 at more than ten times the cost of synthetic
DMARDs. [6] With the expanded use of biologics, drugs are
beginning to replace in-patient care as the greatest source of direct
costs, [7–9] and differences in access to biologics will likely become
the key variable in RA cost of illness across countries. [7] Used in
patients with severe disease, biologics are currently not recom-
mended as a first-line therapy due to safety and cost concerns. [10]
While model results have demonstrated that early biologic
initiation results in lower costs and improved quality-adjusted life
expectancy, [11,12] real-life data are lacking on the mid- to long-
term impact of biologics on the direct costs of RA, including the
time of initiation of biologic therapy. Furthermore, cost of illness
data from larger samples and among patients with early or mild
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disease is needed, as the majority of studies to-date have included
only patients with established RA [13].
The Etude et Suivi des Polyarthrites Indiffe´rencie´es Re´centes (ESPOIR)
cohort is a multicentric, prospective study of French patients with
early arthritis (EA). [14] Our objective was to estimate the annual
direct costs of RA among patients in the ESPOIR cohort in their
first four years of illness, to describe the distribution of costs by
resource component and to identify factors associated with costs.
In order to explore the economic and clinical impact of the time of
biologic initiation, we sought to compare direct costs and disease
activity between RA patients prescribed a biologic in their first
year of disease treatment (‘first-year biologic’, FYB) and those
prescribed a biologic later, after their first year of treatment (‘later-
year biologic’, LYB).
Patients and Methods
Patients
The ESPOIR cohort recruited 813 patients in France between
2002 and 2005. [14] Patients were aged 18–70 years, had a
rheumatologist’s diagnosis of probable or certain RA or EA
potentially becoming RA, with at least two swollen joints and
symptom onset – first persistent arthritis according to the patient -
between six months and six weeks before inclusion. History of
DMARD use was limited to within two weeks before inclusion,
Table 1. Baseline patient characteristics.
Study population stratified on treatment strategy
Whole pop. Study pop. No DMARDs Synthetic DMARDs only FYB LYB
(n=813) (n =548) (n=51) (n =389) (n =42) (n=66)
Age in years 47.6 (12.6) 49.2 (11.6) 50.6 (11.1) 49.9 (11.5) 46.7 (12.2) 45.8 (11.9)
Female 624 (76.8%) 422 (77.0%) 36 (70.6%) 305 (78.4%) 33 (78.6%) 48 (72.7%)
Married 503 (61.9%) 358 (65.3%) 36 (70.6%) 258 (66.3%) 24 (57.1%) 40 (60.6%)
High school diploma 255 (31.4%) 171 (31. 2%) 19 (37.3%) 120 (30.9%) 11 (26.2%) 21 (31.8%)
Population of place of residence
,5.000 274 (33.7%) 199 (36.3%) 24 (47.1%) 137 (35.2%) 12 (28.6%) 26 (39.4%)
.5.000 and ,20.000 152 (18.7%) 100 (18.3%) 7 (13.7%) 76 (19.5%) 5 (11.9%) 12 (18.2%)
.20.000 366 (27.8%) 249 (45.4%) 20 (39.2%) 176 (45.2%) 25 (59.5%) 28 (42.4%)
Monthly household income (J)
not reported 35 (4.2%) 20 (3.7%) 2 (3.9%) 11 (2.8%) 2 (4.8%) 5 (7.6%)
,1.220 154 (19.0%) 83 (15.2%) 9 (17.7%) 51 (13.1%) 5 (11.9%) 18 (27.3%)
.1.220 and ,1.830 171 (21.1%) 114 (20.8%) 11 (21.6%) 83 (21.3%) 9 (21.4%) 11 (16.7%)
.1.830 and ,2.440 156 (19.2%) 117 (21.4%) 12 (23.5%) 84 (21.6%) 9 (21.4%) 12 (18.2%)
.2.440 and ,2.745 69 (8.5%) 53 (9.7%) 3 (5.9%) 43 (11.1%) 3 (7.1%) 4 (6.1%)
.2.745 228 (28.1%) 161 (29.4%) 14 (27.5%) 117 (30.1%) 14 (33.3%) 16 (24.2%)
Full health coverage 741 (91.1%) 510 (93. 1%) 46 (90.2%) 364 (93.6%) 38 (90.5%) 62 (93.9%)
Symptom duration (days) 214 (253) 102.1 (50.9) 103.2 (44.7) 98.5 (49.9) 109.8 (68.7) 117.8 (44.8)
Swollen joint count 7.19 (5.4) 7.5 (5.4) 5.8 (5.5) 7.5 (5.4) 9.8 (5.8) 7.8 (4.8)
Tender joint count 8.43 (7.0) 8.5 (7.0) 5.8 (5.9) 8.3 (7.1) 11.7 (6.8) 9.9 (6.7)
ESR (mm/1st hour) 29.43 (24.6) 29.3 (24.6) 19.9 (23.1) 29.0 (24.2) 40.6 (28.2) 30.9 (22.6)
CRP (mg/l) 22.15 (33.6) 21.6 (32.0) 14.5 (23.6) 21.2 (32.3) 28.2 (32.4) 25.2 (35.2)
IgM RF positive 372 (45.7%) 276 (50.3%) 8 (15.7%) 190 (48.8%) 31 (73.8%) 47 (71.2%)
ACPA positive 315 (39.0%) 250 (45.6%) 4 (7.8%) 168 (43.2%) 31 (73.8%) 47 (71.2%)
Typical damage on X-ray 110 (13.6%) 84 (15.3%) 2 (3.9%) 58 (14.9%) 11 (26.2%) 13 (19.7%)
DAS 28 5.11 (1.30) 5.12 (1.30) 4.27 (1.45) 5.08 (1.23) 5.95 (1.16) 5.49 (1.27)
HAQ 0.97 (0.68) 0.97 (0.68) 0.74 (0.65) 0.94 (0.67) 1.37 (0.76) 1.10 (0.65)
Satisfaction of ACR criteria (1987) 600 (73.8%) 417 (76.1%) 23 (45.1%) 305 (78.4%) 38 (90.5%) 51 (77.3%)
Satisfaction of ACR criteria (2010) 641/811 (79.0%) 456 (83.2) 25 (49.0%) 330 (84.8%) 42 (100%) 59 (89.4%)
Physician diagnostic certainty (0–100 VAS) 67.9 (24.5) 71.8 (23.8) 52.5 (23.9) 71.8 (23.6) 81.4 (16.8) 80.7 (19.2)
1st rheumatologist visit after RA onset1 74.9 (76.6) 76.9 (83.2) 63.1 (47.2) 75.9 (79.6) 110.8 (151.2) 70.7 (55.8)
DMARD initiation at 6-month visit 599/757 (79.1%) 452 (82.5%) 0 (0%) 353 (90.8%) 42 (100%) 57 (86.4%)
Hospitalization before baseline 193 (23.9%) 133 (24.4%) 11 (21.6%) 90 (23.1%) 15 (35.7%) 17 (25.8%)
Values are mean values (SD) or number of patients (%).
1Eular Guideline: 1st rheumatologist visit after RA onset ,45 days; ESR = Erythrocyte sedimentation rate, CRP= C-Reactive Protein, DAS-28 =Disease Activity Score 28,
HAQ=Health Assessment Questionnaire, ACR=American College of Rheumatology, VAS = Visual analogue scale, EULAR = European League Against Rheumatism,
DMARD=Disease-modifying antirheumatic drug, ACPA = anti-citrullinated protein antibody.
doi:10.1371/journal.pone.0097077.t001
Timeline of Biologic Initiation on RA Cost
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e97077
while corticoid use was limited to a two-week prescription duration
at a maximum mean dose of 20 mg/day of prednisone (four weeks
for intra-articular injections). Due to the mode of recruitment, the
cohort may be considered representative of the EA patient
population in France and other similar countries. Patients were
followed at one of 14 hospital centres every six months for a period
of two years and every year thereafter. At each study visit after
baseline, data were collected regarding health resource use since
the previous visit, while data on patient sociodemographics,
disease severity (health assessment questionnaire (HAQ) and
Disease Activity Score on 28 joints (DAS-28) scores) and RA
management were collected at every visit. The ethics committee of
Montpellier approved the ESPOIR research programme in July
2002. All the patients signed an informed consent form before
inclusion.
Costing Method: Definition and Sources of Costs
Our analysis included only direct RA costs from the French
health system perspective, all three payers combined (i.e., statutory
health insurance (SHI), complementary health insurance, and
patients), divided between the cost of RA-specific drugs (either
synthetic or biologic DMARDs) and costs of other healthcare
resources. The cost of DMARDs was defined as the cost of the
drugs themselves plus costs related to administration (e.g., day
hospitalisations for intravenous biologics). Other healthcare costs
included consultations with physicians and other health profes-
sionals, symptomatic treatments using non-DMARD drugs,
imaging (X-rays, computerised tomography (CT scans), magnetic
resonance imaging (MRI), gastric endoscopies, colonoscopies),
transportation, hospitalisations (except for biologic administration
-Infliximab, Rituximab, Abatacept – administered exclusively in a
hospital setting) and clinical workups including blood tests.
Because costs associated with the DRG coding version used were
available only until 2007, costs were expressed using J2007 [3].
For both specialists and general practitioners, an average
consultation fee was estimated using 2007 SHI tariffs and average
extra billing. [15,16] Mean psychologist fees were derived from a
survey. [17] Visits to physiotherapists were valued as the average
tariff for patient education in inflammatory arthritis. [18] Nurse
visits were valued as the tariff for 30 minutes of care by a skilled
nurse plus a fixed average travel allowance [18].
Clinical workups were assigned their 2007 values based on
expert opinion for inclusion, monthly and annual blood tests. [18]
Transportation (ambulance and patient transport service) was
Figure 1. Disease activity per period among matched groups of
FYB and LYB users.* 37 FYB users and 37 LYB users were matched for
clinical and sociodemographic baseline characteristics using a logistic
regression propensity score. ** Low disease activity is defined as DAS-
28#3.2.
doi:10.1371/journal.pone.0097077.g001
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valued by calculating an average cost per km and using a national
average distance of 20 km to visit a rheumatologist [19].
Drugs were grouped according to their international nonpro-
prietary names (INN), and their costs were calculated by
estimating mean tariffs per milligram or per dose, weighted for
the volumes sold in France in 2007 based on claims data. [18] The
results were then multiplied by dosage and by prescription
duration in days. Costs were estimated in each of the four
treatment strategies, with patients divided into four mutually
exclusive groups, the first two dividing non-biologic users into two
groups and the last two dividing biologic users into two groups as
well: ‘no biologic use’, synthetic DMARDs only, ‘first-year
biologic’ (FYB) and ‘later-year biologic’ (LYB).
Hospitalisation costs were estimated according to diagnosis-
related groups (DRG) using 2007 [20,21] cost estimations and
were adjusted by the number of days. Costs were calculated for
each six-month (or one-year) period and then summed in order to
obtain the total cost over four years and the mean annual per-
patient cost.
Statistical Analyses
Patient characteristics were described by the mean (SD) or
number (%) and costs by the mean 6 SD (median). Group
comparisons were made using the Student t-test, the Wilcoxon
Mann Whitney-test or the x2-test.
The clinical impact of the time of biologic initiation among
biologic users was assessed by comparing the proportion of
patients with low disease activity (DAS-28#3.2), the proportion of
patients needing assistance from other personnel, the proportion of
patients with RA caused disability, mean HAQ and mean
EuroQol Five Dimensional Questionnaire (EQ-5D-3L) through-
out the study period in groups of FYB and LYB users matched on
baseline characteristics using a logistic regression propensity score
the variables of which were selected using the stepwise selection
method.
A regression analysis was conducted to identify determinants of
total direct costs in the first four years of illness for patients who
had attended all follow-up visits. To assess the timeliness of
biologic initiation, another regression analysis investigated deter-
minants of other (non-DMARD) healthcare costs that reflect the
patients’ healthcare needs and level of disease activity. Because of
the skewed distributions of both primary outcomes and the
hierarchical structure of the data by center, we used generalised
linear mixed models, which have been recommended for this type
of cost data analysis. [22] Specifically, the fitted models were
random intercept gamma regression models with log links.
Coefficients were exponentiated to express effects as rate ratio
(RR) estimates. For each model, the proportion of variance
explained was calculated as the total variance from the fully
unconditional model minus the total variance from the conditional
model, divided by the total variance from the fully unconditional
model. [23] The intraclass correlation coefficient (ICC), which is
the proportion of the total variance that is accounted for by the
center level, for each model was calculated as well. Variables were
selected using the backward elimination method.
Variables used to investigate potential cost factors and to
calculate propensity scores included patient sociodemographics,
disease severity and RA management characteristics. Sociodemo-
graphic variables included age, sex, marital status, income and
health insurance coverage. Disease severity indicators included
hospitalisation at baseline or in the preceding six months (yes/no),
functional ability at baseline expressed in four mutually exclusive
groups (HAQ#0.5; 0.5,HAQ#1; 1,HAQ#2; HAQ.2), [24]
variation in HAQ in the first six months, presence of anti-cyclic
citrullinated peptide (ACPA), presence of IgM rheumatoid factor
at baseline and intensity of pain on a scale of 1 to 6. Effects of the
DAS-28 score on costs were not investigated because it was highly
correlated with the HAQ score (Pearson correlation coeffi-
cient = 0.60, p,0.0001), a fundamental outcome measure in
RA. [24] Moreover, DAS-28 constitutes one of the main criteria
for determining DMARD treatment strategies and thus would be a
confounding factor. [25] RA management characteristics included
physician certainty of RA diagnosis on a 0–100 visual analogue
scale and treatment strategy.
Dropouts and missed study visits may be linked to patients’
disease severity, and thus missing data may lead to bias in cost
analyses. To address this issue and assess the robustness of the
models, sensitivity analyses were conducted using a Markov chain
Monte Carlo (MCMC) multiple imputation (24 cycles) method
based on a multivariate normal distribution. Patients who missed
all study visits and those who died during the study period
remained excluded. Imputations concerned log-transformed costs
per period (12.3% of missing data) as well as the variables FYB
(4.5%) and LYB (22.5%), which were imputed without rounding.
[26] The following variables were used in the imputation model:
all variables tested for the complete case analyses as well as dummy
variables to account for the multicentric structure of the data [27]
and supplementary auxiliary variables correlated with the
variables to be imputed as well as with their missingness. [28]
Data were assumed to be missing at random. Imputed costs per
period were back transformed and then summed. Regression
analyses were performed on each imputed data set, and results
were combined using Rubin’s rules [29].
Statistical analyses were performed using SAS 9.3 (SAS
Institute, Cary, North Carolina).
Results
Study Population
Two-thirds (n = 548) of the 813 patients in the ESPOIR cohort
attended all follow-up visits and were included in the baseline
analysis (Table 1). The majority (71.0%) were treated with
Figure 2. Mean costs per period according to treatment
strategy. (A) Mean total costs according to treatment strategy; (B)
Mean other health resource use costs according to treatment strategy.
doi:10.1371/journal.pone.0097077.g002
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synthetic DMARDs only, while 9.3% received no DMARDs,
7.7% received a FYB and 12.0% received a LYB. LYB received
biologics with a median duration of 2 years after inclusion (mean
duration: 2.29 years, SD: 0.96).
Among the 265 excluded patients, baseline HAQ and DAS-28
scores were not different from the study population’s (p = 0.52 and
p= 0.57, respectively), nor was sex distribution (p= 0.80). How-
ever, excluded patients were slightly younger (45 vs. 49 years,
p = 0.002), fewer were positive for ACPA (24.5% vs. 45.6%, p,
0.0001) and IgM rheumatoid factor (IgM RF) (36.2% vs. 50.4%,
p= 0.0001) and fewer met the 1987 American College of
Rheumatology (ACR) RA criteria (61.1% vs. 76.1%, p,0.0001).
Table 4. Multivariate analysis of the effects of demographic and clinical variables and treatment strategy on total costs over 4
years.
Complete case analysis
(n= 548)
MCMC imputation model
(n =777)
Variables Rate Ratio (95% CI) P-value Rate Ratio (95% CI) P-value
First year biologic use 7.22 (5.59–9.31) ,0.0001 7.74 (5.70–9.78) ,0.0001
Later year biologic use 4.39 (3.58–5.39) ,0.0001 4.54 (3.38–5.70) ,0.0001
HAQ score at baseline: .2 2.25 (1.76–2.88) ,0.0001 2.10 (1.52–2.67) 0.0002
HAQ score at baseline: 1 to #2 1.45 (1.23–1.69) ,0.0001 1.50 (1.22–1.78) 0.0006
Variation in HAQ score (per 0.25-point increase) between
baseline and 6 month visit
1.07 (1.03–1.10) ,0.0001 1.06 (1.03–1.10) 0.0007
Doctor’s evaluation of RA diagnostic ,50% at baseline 0.73 (0.62–0.86) 0.0002 0.78 (0.65–0.91) 0.0014
Hospitalisation at baseline 1.32 (1.13–1.54) 0.0005 1.29 (1.07–1.50) 0.0083
Lives with a partner at baseline 0.67 (0.57–0.79) ,0.0001 0.69 (0.58–0.81) ,0.0001
Age (per 10-year increase) at baseline – – 1.11 (1.05–1.18) 0.0009
Full health coverage – – 0.67 (0.48–0.87) 0.0014
Family income.J1220 – – 1.28 (1.03–1.52) 0.0264
Proportion of variance explained by model 53% 46% (44%–48%)1
ICC 4.15% 5.97% (4.05%–8.53%)1
The reported Rate Ratios describe the variations in costs expressed as a multiplicative factor for patients presenting the associated characteristic compared to those
who did not, all other things being equal.
MCMC=Markov Chain Monte Carlo; CI = Confidence Intervalle; HAQ=Health Assessment Questionnaire; RA = Rheumatoid Arthritis; ICC= Intraclass Correlation
Coefficient.
1Median and range for all 24 imputed datasets.
doi:10.1371/journal.pone.0097077.t004
Table 5. Multivariate analysis of the effects of demographic and clinical variables and treatment strategy on other health resource
use costs over 4 years.
Complete case analysis
(n =548)
MCMC imputation model
(n=777)
Variables Rate Ratio (95% CI) P-value Rate Ratio (95% CI) P-value
Later year biologic use 1.64 (1.32–2.05) ,0.0001 1.73 (1.28–2.18) 0.0016
HAQ score at baseline: .2 2.43 (1.87–3.17) ,0.0001 2.66 (1.87–3.45) ,0.0001
HAQ score at baseline: 1 to #2 1.48 (1.24–1.76) ,0.0001 1.51 (1.22–1.81) 0.0007
Variation in HAQ score (per 0.25-point increase) between
baseline and 6 month visit
1.06 (1.03–1.10) 0.000 1.08 (1.04–1.11) ,0.0001
Doctor’s evaluation of RA diagnostic ,50% at baseline 0.76 (0.64–0.92) 0.004 0.82 (0.67–0.96) 0.0114
Hospitalisation at baseline 1.38 (1.16–1.64) 0.000 1.29 (1.06–1.51) 0.0113
Lives with a partner at baseline 0.65 (0.55–0.77) ,0.0001 0.72 (0.60–0.84) ,0.0001
Age (per 10-year increase) at baseline – – 1.10 (1.03–1.17) 0.0033
Proportion of variance explained by model 22% 17% (16%–19%)1
ICC 4.85% 5.85% (4.21%–8.02%)1
The reported Rate Ratios describe the variations in costs expressed as a multiplicative factor for patients presenting the associated characteristic compared to those
who did not, all other things being equal.
MCMC=Markov Chain Monte Carlo; CI = Confidence Intervalle; HAQ=Health Assessment Questionnaire; RA = Rheumatoid Arthritis; ICC= Intraclass Correlation
Coefficient.
1Median and range for all 24 imputed datasets.
doi:10.1371/journal.pone.0097077.t005
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The study population for the regression sensitivity analyses
(n = 777) included the 813 cohort patients, less the seven who died
during the study period and the 29 patients who attended no study
visits following inclusion.
Impact of Time of Initiation of Biologics on Disease
Activity
A comparison of groups of FYB and LYB users matched on
baseline characteristics (baseline DAS-28 and HAQ scores not
significantly different among two groups of equal sizes (n = 37)
with p= 0.93 and p= 0.68 respectively after matching) shows that
over the entire study period, FYB users compared to LYB users
display lower proportions of patients with low disease activity
(DAS-28#3.2) (see Figure 1), lower proportions of patients
needing assistance for daily activities, lower proportions of patients
with RA caused disabilities, lower mean HAQ scores and higher
mean EQ-5D-5L scores (see Table 2).
The variables retained in the propensity score model were:
satisfaction of ACR criteria, HAQ level and home ownership
status.
Descriptive Cost Analysis
The breakdown of costs by resource component is shown in
Table 3. The mean annual total cost per patient over the four-year
period was J3,612, with DMARD costs accounting for nearly half
that amount. It can be seen in Figure 2 (A) that total costs
increased year by year over the study period in all treatment
strategy groups except for FYB users whose mean annual total
costs decreased between year three and year four. Among other
costs, hospitalisation was the largest component, constituting one-
third of total costs with wide variation among groups. Hospital-
isation costs for LYB users were more than three times higher than
those of patients not treated with DMARDs.
For patients receiving biologics, DMARDs constituted the
highest share of total costs. For FYB patients the mean annual cost
per patient was more than five times higher than that of the rest of
the population, nearly twice that of LYB users and nearly eight
times that of patients receiving only synthetic DMARDs.
Other healthcare costs were one-third lower among FYB
patients compared to LYB patients, representing an average
annual offset of J1,042. Healthcare costs of FYB patients
remained comparable to patients who received no biologic
treatment (Figure 2 (B)), although FYB patients were likely to
have a more active disease at inclusion (mean DAS-28:5.95 vs.
4.99, p,0.0001 and mean HAQ: 1.37 vs. 0.91, p,0.0001; see
Table 1). This contrasted with LYB patient costs, which remained
higher than those in all other groups and increased regularly over
the four-year period with a peak increase 24 months after
inclusion.
Grouping LYB patients by year of biologic initiation revealed
that their total mean annual costs decreased with later initiation of
biologics (total costs in order of year of biologic initiation: J10,661
(n = 32, 2nd year after inclusion), J7,592 (n= 16, 3rd year after
inclusion) and J5,384 (n= 18, 4th year after inclusion) respective-
ly), while their other mean annual costs remained comparable
(healthcare costs by year of biologic initiation: J3,032, J2,941
and J3,053 respectively). Inferential statistics were not produced
due to the small size of these groups.
Factors Associated with Costs
The results of the multivariate regression analyses of total costs
and other healthcare costs are shown in Tables 4 and 5. The
reported RR describe the variations in costs expressed as a
multiplicative factor for patients presenting the associated charac-
teristic compared to those who did not, all other things being
equal.
The total and other healthcare costs models were similar in
terms of significance and magnitude of effects. Higher HAQ scores
at baseline, increase in HAQ score between baseline and the six-
month study visit and hospitalisations at baseline or in the six
months prior to inclusion were associated with higher costs,
whereas living with a partner and having a doctor’s certainty of
RA diagnostic below 50% had the opposite effect. The strongest
effects on costs were found for the use of biologic treatments and
HAQ.
While the biologic treatment strategy induces the highest
increase in total costs, with FYB showing a greater impact than
LYB, only LYB shows a significant relation with other healthcare
costs: plus 60% compared to all other patients.
Sensitivity analyses showed similar results but with additional
significant effects. Higher age at baseline increased both types of
cost, while high family income and full health coverage were only
related to total costs with respectively increasing and decreasing
effects.
The total costs model explained more than 50% of observed
variations, while only 22% were explained by the other healthcare
cost model. Furthermore, those variations were primarily driven
by differences between patients rather than between medical
centres’ practices, with intraclass correlation coefficients lower
than 5% when adjusted for patient-level variables.
Discussion
Our study reported the costs of a large sample of EA patients,
more than 80% of whom satisfied the RA classification criteria.
[30] With 71% of patients using only synthetic DMARDs and
19.7% using biologics, mean annual total costs in the cohort were
J3,612 while mean other healthcare costs were J1,844.
High costs of RA in several countries have been described from
both the societal and public payer perspectives, [7,13] with the
latter most often estimating only direct costs of RA treatment. A
recent overview in western countries estimated the average annual
direct costs in J2007 at J4,208, [13] while another reported
substantially higher costs in western European countries (J15,135)
than in central or eastern European countries, (J3,532). [7] The
ESPOIR cohort’s direct costs were lower than those previously
reported in the literature. [13,31,32] This could be partially
explained by the fact that the present study explores the early
stages of the disease, for which surgery and disability care are
limited. Moreover, while previous studies found hospitalisations to
be the largest cost share, [13,33] we found that it is currently
attributable to RA-specific drug costs, particularly biologic
therapies, which represent almost half of the direct four-year
costs. The economic impact is significant for the French statutory
health insurance, which bears almost the full cost of these drugs.
Our analysis revealed wide variations in direct medical costs
among patients in the first four years of RA treatment depending
on the treatment strategy. As expected, total costs over four years
were over 70% higher for patients with FYB use compared to
patients with LYB use. This difference was due to the increased
cost of biologic DMARDs, as other costs were in fact lower among
FYB patients compared to LYB users over the period. As shown in
Figure 1 (B), FYB users’ other healthcare costs remained at a lower
level throughout the four-year study period than those of LYB
users, indicating greater diminishment in disease progression
among FYB users, which is supported by a higher proportion of
patients with low disease activity (DAS-28#3.2) (see Figure 2),
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lower rates of needed assistance and RA caused disability, higher
HAQ levels and lower EQ-5D-3L utilities (see Table 2) among
FYB users’ after matching on baseline characteristics. Further-
more, FYB patients’ other costs over four years did not differ
significantly from those of patients who did not need biologic
therapy, while they were more than 60% higher for LYB patients.
This is consistent with previous findings according to which very
early suppression of disease activity is likely to reduce patient costs
[34].
As other authors have found [35,36] another significant cost
driver was disease severity, as revealed by high HAQ values. In
addition, when physicians were more confident in the RA
diagnosis, they were more likely to use a step-up strategy [37,38]
resulting in higher resource use.
We acknowledge some limitations regarding data quality,
availability and follow-up and statistical analyses. Information
related to blood tests and analgesic dosages was not recorded in a
standardised manner, and thus we used standard packages defined
by an expert. Transportation costs were also standardised, as
covered distances were not reported. However, the impact of these
limitations on the reported results should be small because they
account for a minor proportion of total costs: blood tests (,5%),
analgesics (,2%) and transportation (,1%). There was a
substantial degree of missing values, with 33% of patients missing
at least one follow-up visit. However, sensitivity analyses found the
models to be robust. In addition, one may question the impact
memory bias [39] may have on the quality of the data collected
retrospectively given the length of time between study visits.
Moreover, the overall study period may have been too short to
reveal the longer term impact of biologic therapies on costs.
Finally, we used 2007 prices and not more recent data. However
the mean annual total costs in the cohort for 2011, obtained by
applying the evolution of the consumption of care and medical
goods price index in France was estimated at J3,616 which is
quite similar to our 2007 results [3].
In our statistical analyses, the multiple imputation method we
used to address the problem of missing data in the sensitivity
analyses may have resulted in bias. We undertook log transfor-
mations of costs per period prior to implementing the multiple
imputation in order to approach normality and obtain exclusively
positive imputed costs following back transformation. Although
some experts recommend such transformations, [40] more recent
research has drawn attention to the limitations of this method,
including degradation of the relationships between variables in the
imputation model resulting in bias, and suggested approaches
based on flexible non-normal distributions [41].
Our analysis suggests that early use of biologics may reduce
other healthcare costs by slowing the evolution of the disease. We
do not know the extent to which the high direct costs incurred
from early use of biologics costs may be balanced in part by other
health care cost offsets due to the reduction in the need for surgery
or other interventions beyond the fourth year of the disease.
Moreover, recent price reductions for biologics could make them
more cost-effective, [42] thereby decreasing resistance to early use
that may improve patients’ lives.
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